Kim Deog Kyeom, Lee Sei Won, Yoo Chul-Gyu, Kim Young Whan, Han Sung Koo, Shim Young-Soo, Yim Jae-Joon
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, 28 Yongon-Dong, Chongno-Gu, Seoul, 110-744, Republic of Korea.
Chest. 2005 Oct;128(4):2218-22. doi: 10.1378/chest.128.4.2218.
The aim of this study was to elucidate the clinical characteristics and treatment responses of tuberculosis developing in patients receiving anticancer chemotherapy.
Retrospective case-control study.
The Seoul National University Hospital, a tertiary referral hospital in South Korea.
From January 1, 2000, to July 31, 2004, patients with tuberculosis detected during the course of anticancer chemotherapy were enrolled as cases. Age- and sex-matched tuberculosis patients without any malignant disease were selected as control subjects.
Twenty-four patients and 48 control subjects were enrolled. Their mean +/- SD age was 56.3 +/- 14.3 years, and the male-to-female ratio was 3:1. The most common malignancy was gastric cancer (43%). Lymphoma (17%), lung cancer (8%), and head and neck cancer (8%) were also common. In both groups, the lung was the most common site of tuberculosis involvement (87.8% and 79.2%, retrospectively). The presence of scar tissue suggesting old tuberculosis on radiography was more common in patients with tuberculosis receiving anticancer chemotherapy (66.7% vs 43.8%, p = 0.07). No difference in radiographic severity was observed between groups. A regimen based on first-line antituberculosis drugs was started in all subjects. Frequency of completion of the expected antituberculosis chemotherapy was lower in patients with tuberculosis developing with anticancer chemotherapy (58.3% vs 79.2%, p = 0.02), but it was not different after excluding the loss due to progression of underlying malignancies. Bacteriologic/radiographic responses to treatment and toxicity of antituberculosis medication sufficient to change or stop treatment were not different in both groups.
With regard to radiographic and clinical responses to antituberculosis treatment, tuberculosis developing during anticancer chemotherapy is not clinically different from tuberculosis developing in ordinary situations. Findings in this study suggest that anticancer chemotherapy is not an obstacle in treating tuberculosis.
本研究旨在阐明接受抗癌化疗的患者发生结核病的临床特征及治疗反应。
回顾性病例对照研究。
韩国三级转诊医院首尔国立大学医院。
2000年1月1日至2004年7月31日期间,在抗癌化疗过程中检测出结核病的患者作为病例组。选择年龄和性别匹配、无任何恶性疾病的结核病患者作为对照组。
共纳入24例患者和48例对照。他们的平均年龄±标准差为56.3±14.3岁,男女比例为3:1。最常见的恶性肿瘤是胃癌(43%)。淋巴瘤(17%)、肺癌(8%)和头颈癌(8%)也较为常见。两组中,肺部都是结核病最常见的受累部位(回顾性分析分别为87.8%和79.2%)。在接受抗癌化疗的结核病患者中,X线片上提示陈旧性结核的瘢痕组织更常见(66.7%对43.8%,p = 0.07)。两组间X线严重程度无差异。所有受试者均开始使用基于一线抗结核药物的方案。抗癌化疗过程中发生结核病的患者完成预期抗结核化疗的频率较低(58.3%对79.2%,p = 0.02),但排除因基础恶性肿瘤进展导致的失访后无差异。两组对抗结核治疗的细菌学/影像学反应以及足以改变或停止治疗的抗结核药物毒性无差异。
关于抗结核治疗的影像学和临床反应,抗癌化疗期间发生的结核病与普通情况下发生的结核病在临床上并无不同。本研究结果表明,抗癌化疗并非治疗结核病的障碍。